Trastuzumab Deruxtecan + Bevacizumab
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer
Trial Timeline
Mar 19, 2025 → Jan 31, 2032
NCT ID
NCT06819007About Trastuzumab Deruxtecan + Bevacizumab
Trastuzumab Deruxtecan + Bevacizumab is a phase 3 stage product being developed by Daiichi Sankyo for Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06819007. Target conditions include Ovarian Cancer.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Cancer were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06819007 | Phase 3 | Recruiting |
| NCT06271837 | Phase 2 | Recruiting |
Competing Products
20 competing products in Ovarian Cancer